Overview

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of the conjunctiva), and external photography whenever possible. 2. To establish the safety profile in this patient population using clinical examination including slit lamp biomicroscopy, and evaluation of the tear film with Schirmer's test. 3. To establish the dosimetry for Zevalin in the orbit in the first 3 patients who agree to undergo dosimetry.
Phase:
N/A
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Biogen
Treatments:
Antibodies, Monoclonal
Rituximab